Topics:
Hematologic Malignancies • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • Hematology • NCI-CCC Lymphoma Tumor Board Question • City of Hope
What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?
Answer from: at Community Practice
This sounds like the patient where a CART may make sense. If that's not an option for whatever reason, I may go to bi-specific over say, copanlisib at this point. I suppose if EZH2 mutated, tazamezostat might be an option, but less appealing in a young otherwise healthy person.
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
CART makes the most sense in this context.